StockData
Cellyan Biotechnology Co., Ltd logo

Cellyan Biotechnology Co., Ltd (HKPD) income statement

HKPDNasdaqWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends March 31
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Mar 31, 2026Last filing: 20-F on Aug 7, 2026Score 3/30
$1.33−0.19 (-12.76%)

Close on Nov 18, 2026Market cap $21.75MP/E –Yield –

Cellyan Biotechnology Co., Ltd income statement

Ratios

Latest available, balances at Mar 31, 2026

Profitability, FY2026

Gross margin
10.3%
Operating margin
-17.8%
Net margin
-8.5%
Return on equity, FY2026
-15.5%

Financial strength

Current ratio
3.86
Debt to equity
–
Debt to assets
–
Cash to current liabilities
6.9%

Valuation

P/E ratio
–
Price to sales
1.62
Price to book
2.26
Dividend yield
–

See a number that looks wrong?